key: cord-0696732-m4b1q2w8 authors: Cheng, Zhangkai J.; Huang, Huimin; Zheng, Peiyan; Xue, Mingshan; Ma, Jing; Zhan, Zhiqing; Gan, Hui; Zeng, Yifeng; Lin, Runpei; Li, Shiyun; Zhong, Ruifen; Li, Siping; Wang, Hongman; Sun, Baoqing title: Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization date: 2022-03-16 journal: Allergy DOI: 10.1111/all.15271 sha: 4940204ec76a818aff0f55f045d52576aac59387 doc_id: 696732 cord_uid: m4b1q2w8 BACKGROUND: The inactivated Sinopharm/BBIBP COVID‐19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low‐ and middle‐income nations due to their low storage requirements. OBJECTIVE: This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, and the intensified antibody response elicited by the booster. METHODS: A total of 353 healthy adult participants, aged 20–74 years, were recruited in this multicenter study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine‐induced virus‐specific antibody levels (SARS‐CoV‐2‐IgA/IgM/IgG), conventional virus neutralization test (cVNT), pseudovirus neutralization test (pVNT), and surrogate virus neutralization test (sVNT) were monitored over multiple time points. RESULTS: Neutralizing titers induced by the two doses of inactivated vaccine for COVID‐19 peaked at Month 2 and declined to 33.89% at Month 6. Following the booster dose, elevated levels of antibodies were induced for IgA, IgG, and neutralizing antibodies, with neutralizing titer reaching 13.2 times that of before the booster. CONCLUSION: By monitoring the antibody titer levels postvaccination, this study has shown that serum antibody levels will decrease over time, but a notable spike in antibody levels postbooster highlights the anamnestic immune response. This signifies that the protection capability has increased following the injection of booster immunization. The coronavirus disease 2019 (COVID- 19) global pandemic caused by the contagious virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically accelerated vaccine development. 1 Vaccines can engage the body's immune system to guard against the disease, such as the production of protective neutralizing antibodies. The development of new vaccines has been speed up from 10-15 years to 1-2 years, 2 with numerous vaccines being tested quickly in phase I, II, and III clinical trials followed by application in different regions. This was made possible by the knowledge and experience gained during previous epidemics, the maturation of advanced technological platforms, and the timely and large-scale investment of corporations, governments, and nonprofit organizations without regard for cost. 3 However, because these vaccinations are being developed and applied at such a quick speed, there are worries about not only their effectiveness in providing immunological protection to the community, but also the longevity of immunity in the population. This study monitored specific antibody levels (IgA/IgM/IgG), cVNT, pVNT, and sVNT tests in 353 healthy adult subjects over the course of vaccination. The first two injections of the vaccine induce humoral responses with a peak at 2 months. Following the booster dose, IgA, IgG, and neutralizing antibodies increase with a neutralizing titer 13.2 times higher than before the booster. individuals completed a questionnaire survey on adverse symptoms. However, a number of individuals dropped out of the study during follow-up monitoring, resulting in a final count of 353 participants (106 male, 247 female), aged 20-74 years (median: 33), being included in the analysis. The sample size was not determined based on the statistical power calculation. None of the participants have been exposed to SARS-CoV-2 infection before or throughout the study, due to China's zero-COVID approach and continual RT-PCR screening during a small-scale local outbreak in Guangzhou in June 2021. 7 Main inclusion criteria: participants must be healthy, aged 18 and above, willing to participate, able to understand, and sign the informed consent. Main exclusion criteria: 1. Those who are allergic to the active ingredient, any inactive ingredient, or substance used in the production process of the vaccine, or those who have previously been allergic to the same kind of vaccine; 2. those who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioneurotic edema, dyspnea, etc.); 3. those suffering from uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.); 4. those who are febrile, or suffering from acute diseases, or acute episodes of chronic diseases, or patients with uncontrolled serious chronic diseases; 5. pregnant women; and 6. those who had had a positive PCR test, or previous history of COVID -19 infection. After providing written informed consent by themselves, participants were injected homologously with a two-shot regiment (28 days apart) of 4μg dose of β-propiolactone-inactivated, aluminum hydroxide-adjuvanted Sinopharm/BBIBP COVID-19 vaccine, followed by a third booster injection 7 months following the initial injection. The vaccine was developed by the Beijing Institute of Biological Products (Beijing, China) and manufactured as previously described. 8 Surrogate virus neutralization test titers in human serum samples were identified in vitro using RBD-neutralizing antibodies (for wildtype virus) utilizing the competitive chemiluminescence method, using the automated analytical apparatus Axceed 260 described above, with accompanying immunoassay test kits. The RLU obtained with Axceed 260 would be converted to a final titer readout, in titer units of AU/ml. Because the instrument has an upper detection titer limit of 30, if the final titer readout was greater than 30, the experiment was repeated with the sample diluted 10 times. If the readout remained above 30, the sample would be further diluted 2 times (total 20x dilution). The test kit consisted of reagent 0 (magnetic particle receptor angiotensin-converting enzyme (ACE2) antigen), reagent 1 (alkaline phosphatase-labeled S protein RBD), calibrator 1, calibrator 2, and other necessary auxiliary reagents. During a test, reagent 0, reagent 1, and serum samples were added to the reaction tube. If the sample contained neutralizing antibody, it would compete with magnetic particle-labeled ACE2 antigen to bind S protein RBD. Free components were then rinsed away. Substrate solution was added, substrate solution luminescence was catalyzed by alkaline phosphatase, and the RLU of each sample tube was quantified. The RLU of the sample negatively correlated with the concentration of SARS-CoV-2-neutralizing antibody in the sample, allowing us to calculate the titer of sVNT (in units of AU/ml) in human serum. Titer levels of ≥2 AU/ml were regarded as positive (threshold designed by manufacturer). Geometric mean titer (GMT) of antibodies were calculated using the geometric mean of the titer levels, and their 95% confidence interval (CI) was calculated with the Student's t distribution on logtransformed data and then back transformed. Participants were stratified according to age and sex. Comparison between titer-level differences between two groups was performed using the Mann-Whitney Wilcoxon test. One-way analysis of variance (one-way ANOVA) was used to analyze the differences between mean values of different time points. Correlation analyses were performed using Pearson correlation analysis and the permutation test for Pearson's correlation coefficient. A value of p < .05 was considered to be significant. All calculations and figures were produced using MATLAB ® R2021a (Natick, MA, USA). The reported adverse reactions from the 479 recorded questionar- The total positive rate and GMT of sVNT for each age group and time point are shown in Table 1 . Additional results for SARS-CoV-2-IgA/IgM/IgG antibody titer levels for each age group and time point are shown in Tables S1, S2 and S3. Figure 1 shows the spe- pVNT, and sVNT). After the first two injections, a similar and increasing trend of neutralization titer was observed. Figure 3C shows that the GMT of sVNT peaked at 6.8 AU/ml (95% CI, 6.0-7.7), and at Finally, levels of antibodies grouped by age (i.e., ≤40 y.o. and >40 y.o.) at each monitoring point are presented in Figure 4 . Similarly, levels of antibodies grouped by gender at each monitoring point are presented in Figure 5 . The results showed no statistically significant differences in antibody titer levels between different age groups and genders. Figure 6 shows that the measured SARS-CoV-2-IgG correlates with sVNT titer levels (r = .647, p = 3 * 10 −162 ). The most effective regimen for COVID-19 vaccination is still unknown as data continue to evolve following the waning of immunity cine decays rapidly after injection, but protection against severe COVID-19 cases remains high after 6 months. 15 In the case of this study, the actual efficacy of the vaccine remains unclear, as the threshold of protection for antibody titers against COVID-19 remains unknown. Another study discovered that the occurrence of COVID-19 breakthrough infections is correlated with the time from injecting the BNT162b2 vaccine. 16 Together, all the evidence points to a decrease in the long-term protection of vaccines. However, in addition to inducing neutralizing antibodies, another aspect of the protective power of vaccines is dependent on the formation of immune memory. The findings of this study indicate that immunity against SARS-COV-2 induced by the third dose of inactivated vaccine helps to provide better immune protection and enhance neutralization titer. Our study has several limitations. First, we did not evaluate B- and T-cell responses after vaccination. Second, we did not include people with a higher risk of infection, more severe prognosis, or other comorbidities. Finally, more real-world studies based on largescale outbreaks, and data from preclinical trials, are needed in future to comprehensively assess the immune persistence of inactivated vaccines and determine neutralizing antibody thresholds associated with preventive clinical outcomes. The antibody titer time profile for the two age groups (≤40 and >40 years old). The curves connect the geometric mean end-point titers (GMTs) at each monitoring point, with the two postbooster monitoring points combined. Shaded regions denote the 95% CI range of the GMT We found that the inactivated SARS-CoV-2 vaccine, BBIBP-CorV, is safe and well-tolerated in healthy adults. Humoral responses were induced after the first two injections of the vaccine and peaked at 2 months following the initial injection before gradually declining over time. A booster dose considerably elicited the anamnestic immunity, as the neutralizing titer reaches 13.2 folds a month after the booster immunization. The authors would like to acknowledge funding supports by None to report. 2019 novel coronavirus: where we are and what we know SARS-CoV-2 vaccines in development Factors affecting the antibody immunogenicity of vaccines against SARS-CoV-2: a focused review Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Public health measures and the control of COVID-19 in China Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 COVID-19 vaccine boosters: what do we know so far? Protection against Covid-19 by BNT162b2 booster across age groups Considerations in boosting COVID-19 vaccine immune responses WHO validates Sinopharm COVID-19 vaccine for emergency use and issues interim policy recommendations Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19 Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work. The funders of the study took no role in data collection, analysis, interpretation, or writing of the article. Zhangkai J. Cheng https://orcid.org/0000-0002-8621-4119Baoqing Sun https://orcid.org/0000-0002-1671-0723